Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88161461 |
LAW OFFICE ASSIGNED |
LAW OFFICE 113 |
MARK SECTION |
MARK |
http://uspto.report/TM/88161461/mark.png (stylized and/or with design) |
STANDARD CHARACTERS |
NO |
USPTO-GENERATED IMAGE |
NO |
OWNER SECTION (current) |
NAME |
Neurocrine Biosciences, Inc. |
MAILING ADDRESS |
12780 El Camino Real |
CITY |
San Diego |
STATE |
California |
ZIP/POSTAL CODE |
92130 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
OWNER SECTION (proposed) |
NAME |
Neurocrine Biosciences, Inc. |
MAILING ADDRESS |
12780 El Camino Real |
CITY |
San Diego |
STATE |
California |
ZIP/POSTAL CODE |
92130 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
B. Brett Heavner |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
docketing@finnegan.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
B. Brett Heavner |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
docketing@finnegan.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
DOCKET/REFERENCE NUMBER |
14640.1003 |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations for human use for schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome,
Lesch-Nyhan syndrome, and Tourette syndrome, movement disorders, namely, Myoclonus, Huntington's chorea, Levodopa-induced dyskinesia, tardive dyskinesia, dystonia, and tics |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
2 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
11/12/2019 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/David L. Bradfute/ |
SIGNATORY'S NAME |
David L. Bradfute, PhD, JD |
SIGNATORY'S POSITION |
Vice President & Head, Intellectual Property |
DATE SIGNED |
11/01/2020 |
SIGNATORY'S PHONE NUMBER |
202-408-4000 (Applicant's attorney) |
FILING INFORMATION |
SUBMIT DATE |
Mon Nov 02 12:22:38 ET 2020 |
TEAS STAMP |
USPTO/ESU-XX.XXX.X.X-2020
1102122238693759-88161461
-750be2f8df14d6982d85c776
b6543d3f987b87a6ef7d5ec3a
acf90a5ac5e237040-CC-2237
1671-20201030135622799380 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: INGREZZA (stylized and/or with design, see http://uspto.report/TM/88161461/mark.png)
SERIAL NUMBER: 88161461
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Neurocrine Biosciences, Inc., having an address of
12780 El Camino Real
San Diego, California 92130
United States
Email: XXXX
Proposed: Neurocrine Biosciences, Inc., having an address of
12780 El Camino Real
San Diego, California 92130
United States
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 11/12/2019.
For International Class 005:
Current identification: Pharmaceutical preparations for human use for schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome, Lesch-Nyhan syndrome, and Tourette
syndrome, movement disorders, namely, Myoclonus, Huntington's chorea, Levodopa-induced dyskinesia, tardive dyskinesia, dystonia, and tics
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
Correspondence Information (current):
B. Brett Heavner
PRIMARY EMAIL FOR CORRESPONDENCE: docketing@finnegan.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Correspondence Information (proposed):
B. Brett Heavner
PRIMARY EMAIL FOR CORRESPONDENCE: docketing@finnegan.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /David L. Bradfute/ Date Signed: 11/01/2020
Signatory's Name: David L. Bradfute, PhD, JD
Signatory's Position: Vice President & Head, Intellectual Property
Signatory's Phone: 202-408-4000 (Applicant's attorney)
RAM Sale Number: 88161461
RAM Accounting Date: 11/02/2020
Serial Number: 88161461
Internet Transmission Date: Mon Nov 02 12:22:38 ET 2020
TEAS Stamp: USPTO/ESU-XX.XXX.X.X-2020110212223869375
9-88161461-750be2f8df14d6982d85c776b6543
d3f987b87a6ef7d5ec3aacf90a5ac5e237040-CC
-22371671-20201030135622799380